PubMed Health⌕ Search

Biomedical subjects

D T Finegood

Publications and source records attributed to D T Finegood.

At least 55 records · Page 3Linked to original sources
PubMed1994

Retrograde versus antegrade cannulation in the intravenous glucose tolerance test.

To investigate whether drawing blood from a retrogradely cannulated hand vein rather than an antegradely cannulated arm vein improves reproducibility in the intravenous tolerance test (IVGTT) we compared these two methods directly by drawing blood from the two sites on the same arm simultaneously. We found no difference in intrasubject coefficients of variation for the measurement of insulin response to glucose (21.5% vs. 22.5%) or insulin sensitivity (22.8 vs. 24.7%) for these two methods. However, the values for insulin response to glucose were significantly increased when blood was drawn from the hand site (410.1 vs. 328.7 pM, P < 0.05). In addition, the failure rate for studies using the retrogradely cannulated hand vein was significantly increased (5% of arm veins vs. 20% of hand veins cannulated, P < 0.05) particularly in female subjects. In conclusion, drawing blood samples from a retrogradely cannulated hand vein appears to have no effect on the reproducibility of the intravenous glucose tolerance test. The acute insulin response to glucose obtained from samples drawn in this manner is, however, significantly increased and this should be borne in mind when comparing results from centers using these different methods.

Adult↗
PubMed1994

Gender differences in the metabolic response to graded numbers of transplanted islets of Langerhans.

Gender differences after treatment with streptozotocin (STZ) have been previously reported; however, differences in the glucose response to islet transplantation in STZ-induced diabetes in male and female rats after islet transplantation have not been examined. Male and female Wistar-Furth rats were made diabetic using STZ (55 mg/kg BW) and then given an intraportal islet transplant. Control animals received sham injections and sham transplant surgery; diabetic animals received STZ and sham surgery. In male animals, islet grafts contained 0 (diabetic), 250, 500, 1000, 1500, 2000, and 3000 islets; in female rats, grafts were made up of 0, 500 700, 750, 1000, or 2500 islets. STZ treatment had more dramatic effects on male than female rats. During the diabetic phase, body weights of male rats were significantly reduced compared to those of control male animals; this was not observed among females. Although all STZ-treated animals were hyperglycemic, plasma glucose levels in male diabetic rats were significantly higher than those in females during this phase (29.8 +/- 2.1 vs. 24.6 +/- 0.6 mM). After islet transplantation, body weight gain was positively associated with the number of islets transplanted in male rats (r2 = 0.59; P < 0.01), but not in females (r2 = 0.09; P > 0.8). In both male and female rats, animals that received 1000 islets or more were generally normoglycemic by 3 weeks posttransplant (males, 10.8 +/- 2.2 mM; females, 7.1 +/- 0.2 mM). Approximately 60% of male and female animals that received 500 islets achieved a reduction in plasma glucose levels. Mean plasma glucose levels were 17.2 +/- 2.3 in the females and 22.6 +/- 1.0 mM in males. However, a significantly larger proportion of female 500-islet animals (6 of 16) achieved a plasma glucose level of 9.5 mM or less compared with males receiving 500 islets (2 of 30). Multivariate regression analysis suggests that sex and islet number interact to affect glycemic normalization after islet transplantation. Gender differences appear to influence body weight and plasma glucose responses to islet transplantation. This finding may have particular relevance when a marginal number of functional islets are available.

Animals↗
PubMed1993

Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related.

We studied the survival of 5 groups of apancreatic mongrel dogs that received 30 days of treatment with CsA adjusted to 300 micrograms/L, rapamycin (0.05 mg/kg/day), both, or no immunosuppression after intrasplenic allotransplantation with purified pancreatic islets. Autografts survived indefinitely. Neither CsA nor rapamycin alone at low doses showed significant increase in islet allograft survival: 6.2 +/- 1.7 and 5.0 +/- 1.1, respectively, versus 3.4 +/- 1.0 days in controls. Dogs treated with low doses of both CsA and rapamycin demonstrated prolongation of graft function to 23.6 +/- 13.2 days (P < 0.05). These findings support synergism between these 2 agents, especially as CsA was not shown to increase trough rapamycin blood concentration when given together. In the combined treatment group, a significant (r = 0.90, P < 0.001) relationship was found between rapamycin blood levels and graft survival. Animals having trough rapamycin concentrations > 10 micrograms/L had significantly (P < 0.05) prolonged graft survival, which suggests that dosing of rapamycin according to blood levels may optimize the effectiveness of the drug. Given at these low doses, combination CsA and rapamycin gave no evidence of adverse effects as measured by hepatic and renal function tests, histology, or electron microscopy.

Animals↗
PubMed1993

Factors determining glucose tolerance in patients with thalassemia major.

To better understand the pathophysiology of glucose intolerance secondary to iron overload in patients with thalassemia major, we performed tolbutamide-modified frequently sampled iv glucose tolerance tests (FSIGTs) in 10 thalassemic patients (6 males and 4 females; 21.7 +/- 1.2 yr old; body mass index, 19.7 +/- 0.6 kg/m2) and 10 healthy controls (5 males and 5 females; 22.4 +/- 1.3 yr; body mass index, 20.6 +/- 0.5 kg/m2). Insulin secretion and action were quantified by application of the minimal model of glucose kinetics and the combined model of insulin and C-peptide kinetics to the FSIGT data. The insulin sensitivity index was significantly lower in thalassemia patients [72 +/- 12 min-1(nmol/mL)] compared to controls [158 +/- 21 min-1(nmol/mL); P = 0.0026]. The integrated insulin response during the FSIGT was significantly greater in thalassemia patients than in controls after tolbutamide injection (P = 0.042). The difference in insulin levels was apparently due to reduced hepatic insulin extraction in thalassemia (78 +/- 2% vs. 68 +/- 3%; P = 0.0251). Seven of the 10 thalassemia patients were studied prospectively at 6-month intervals for 6-12 months. Repeated measures analysis of variance indicated that across a 6-month interval, there was a decrease in the total integrated insulin response (P = 0.002), with no change in insulin sensitivity (P = 0.86). In conclusion, patients with thalassemia major have significant insulin resistance, which may be compensated for by an elevated circulating insulin level. The elevated insulin level in response to tolbutamide appears to be due to reduced hepatic extraction of insulin and not to an enhanced insulin secretory response. Over time, patients with thalassemia experience a reduction in their circulating insulin levels. Persistent insulin resistance along with a progressive reduction in circulating insulin levels may lead to glucose intolerance and diabetes mellitus, which have a high prevalence in patients with thalassemia major.

Adolescent↗
PubMed1993

Insulin secretory function in relation to transplanted islet mass in STZ-induced diabetic rats.

In vivo insulin secretion was quantified as the AIRg or AIRa in islet-transplanted rats. Male Wistar-Furth rats previously made diabetic by STZ administration (55 mg/kg) were transplanted with 500, 1000, 2000, or 3000 islets infused into the portal vein (n = 12-14 per group) and were compared with sham-treated controls (CN, n = 16). At 4-5 wk posttransplantation, no significant differences were noted in the FPG or fasting plasma insulin of the experimental groups (P > 0.05). Body weight, however, was 10% less (P < 0.05) in rats receiving 500 islets than in controls, indicating an effect of beta-cell deficiency on growth rates. To determine the relationship between islet mass and insulin secretion, we measured AIRg after a 0.3 g/kg glucose bolus in fasted conscious animals. A significant correlation was observed between the AIRg and islet number (r = 0.61, P = 0.0001), and both 500- and 1000-islet groups could be differentiated from controls by ANOVA (500: 8%; 1000: 12% of controls; P < 0.05). During a glycemic potentiation protocol, AIRa was measured at basal and elevated blood glucose (approximately 16 mM). At neither basal nor elevated blood glucose was AIRa correlated with islet number (basal r = 0.0622, P = 0.7834; elevated r = 0.3133, P = 0.1667). None of the groups could be differentiated by ANOVA (elevated 500: 37%; 1000, 68% of controls; P > 0.05). Although this study illustrates that AIRa may be better preserved in islet-transplanted rats, AIRg is the better correlate of islet number.(ABSTRACT TRUNCATED AT 250 WORDS)

Analysis of Variance↗
PubMed1993

A new model for the study of mild diabetes during pregnancy. Syngeneic islet-transplanted STZ-induced diabetic rats.

Diabetes during pregnancy carries short- and long-term consequences for the offspring. Improved obstetrical and diabetic care has resulted in decreased morbidity and mortality in the neonate of the diabetic mother. Mild hyperglycemia is still found in both IDDM pregnant women and women with GDM. The long-term consequences of exposure to mild hyperglycemia in utero remain to be determined. In an effort to develop an appropriate animal model of mild diabetes during pregnancy, we mated female STZ-induced diabetic rats previously transplanted with specific numbers of islets of Langerhans (2500, 1000, 700, or 500 islets). Diabetic and nondiabetic sham-transplanted control groups also were studied. During pregnancy, the plasma glucose levels in the diabetic rats and the group receiving 500 islets (26.5 +/- 1.1 and 10.0 +/- 0.8 mM, respectively) were significantly greater than in control animals (5.4 +/- 0.5 mM, P < 0.0001). The mean glucose levels in rats receiving 700 or 1000 transplanted islets (6.8 +/- 0.2 and 6.5 +/- 0.2 mM) also were significantly greater than in control animals (P < 0.001). No difference was evident between control rats and the group receiving 2500 islets (5.8 +/- 0.2 mM). No gross congenital abnormalities were apparent in the offspring. The pup plasma glucose was significantly greater in the offspring of dams receiving either none (diabetic) or 500 islets (10.6 +/- 0.7 and 11.1 +/- 1.1 mM, respectively) compared with the offspring of nondiabetic control dams (4.4 +/- 0.3 mM, P < 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1993

Reduced insulin secretion by repeated low doses of STZ impairs glucose effectiveness but does not induce insulin resistance in dogs.

To investigate the longitudinal relationship between progressive beta-cell dysfunction and other parameters of glucose tolerance, we administered repeated low doses of STZ (10 mg/kg body wt) to dogs at 14-day intervals. STZ was discontinued after 10 doses (n = 4), the onset of fasting hyperglycemia (n = 1), or death (n = 1). Before the initial drug dose and 8 days after each treatment, an insulin-modified frequently sampled intravenous glucose tolerance test was performed to determine the integrated insulin response to glucose (0-19 min), insulin sensitivity, glucose effectiveness, and glucose tolerance. The integrated insulin response to glucose reached a nadir equal to 8% of pretreatment values by completion of the study. Despite this significant reduction in the insulin secretory response to glucose (P = 0.02), fasting plasma insulin, fasting plasma glucose, and insulin sensitivity remained constant throughout the study (P = 0.15, P = 0.71, and P = 0.5, respectively). SG, however, declined significantly below the pre-STZ treatment level in animals that received more than seven STZ doses (> 70 mg/kg STZ cumulatively, P < 0.03). In summary, when fasting normoglycemia is maintained, a 92% reduction in insulin secretory capacity and repeated low doses of STZ may alter glucose effectiveness but does not directly affect insulin sensitivity.

Analysis of Variance↗
PubMed1993

Determinants of clinical remission in recent-onset IDDM.

OBJECTIVE: To assess the relationship of SI and insulin secretion (C-peptide levels) to remission status in recent-onset IDDM. RESEARCH DESIGN AND METHODS: We followed 22 newly diagnosed patients, of whom 16 received immunomodulatory treatment with low-dose (5 mg.kg-1 x day-1) CsA and/or short-term (72 h) methylprednisolone and 6 received standard insulin treatment, at 3-mo intervals for 12 mo. Insulin secretion was assessed by C-peptide levels and AIRglu, which was determined as the area under the insulin response curve, above the fasting level, from 0-10 min after a 0.3 g.kg-1 x i.v. glucose bolus. SI was assessed by the minimal model technique applied to a frequently sampled IVGTT. Clinical remission was defined in those patients who maintained normal range GHb and capillary blood glucose levels < 7.8 mM premeal without insulin therapy for a minimum of 14 days. RESULTS: The rate of clinical remission was not different with immunomodulatory treatment; nor were the metabolic parameters of plasma C-peptide levels, AIRglu, and SI different in the treatment groups. The mean plasma C-peptide level improved significantly at 3 mo and was maintained to 12 mo. AIRglu was grossly subnormal throughout, but a significant improvement was seen at 3 and 6 mo. Mean SI was normalized at 3 and 6 mo but not maintained beyond 9 mo. The maximum rate of clinical remission was seen at 6 mo. CONCLUSIONS: Clinical remission in recent-onset IDDM patients is associated with improvement in both insulin secretion and SI. Although the improvement in basal C-peptide persisted, AIRglu increased only transiently and declined as loss of remission occurred in most patients. Loss of remission to an insulin-requiring state is associated with a decrease in SI.

Adult↗
PubMed1992

Dynamics of glycemic normalization following transplantation of incremental islet masses in streptozotocin-diabetic rats.

We examined the dynamics of glycemic normalization following intraportal infusion of an incremental number of islets of Langerhans in male Wistar-Furth rats. Non-fasted plasma glucose, 24-hr urine volume, and body weight were determined weekly during three weeks of streptozotocin-induced diabetes and for 5 weeks following transplantation of 250-3000 freshly isolated islets. At one week following transplantation, urine volume was inversely proportional to the mass of islets transplanted, but by 5 weeks posttransplantation urine volume was near-normal except in rats receiving only 250 islets. On the basis of the mean data, the nonfasted plasma glucose fell linearly at a rate of 66 mg/dl per week in rats receiving 500-1000 islets, with normoglycemia (147 +/- 9 mg/dl) being obtained 5 weeks posttransplantation. Examination of the individual time courses for nonfasted plasma glucose revealed a different pattern of glycemic normalization, which consisted of sustained hyperglycemia followed by a rapid fall in the plasma glucose level. During the week prior to normalization glucose fell at a rate of 170 mg/dl per week and normoglycemia was obtained from 1 to 5 weeks following transplantation. Examination of the frequency distribution of nonfasted glucose levels suggested a threshold of 300 mg/dl for glycemic normalization. We conclude that the dynamics of glycemic normalization following transplantation of a suboptimal islet mass include sustained hyperglycemia of variable duration, followed by a rapid fall in the nonfasted plasma glucose level. The contributions of changes in insulin secretion and insulin action underlying this dynamic behavior remain to be determined.

Animals↗
PubMed1992

Regulation of glucose turnover at the onset of exercise in the dog.

The early responses of endogenous glucose production (Ra), glucose utilization (Rd), and glucoregulatory hormones to moderate treadmill exercise (12% incline, 100 m/min, 60 min) were examined in dogs. Rd increased rapidly and progressively from the start of exercise. The change in Ra, as estimated with a variable-volume model of glucose kinetics, was biphasic, with an abrupt increase by 8.5 +/- 2.3 mumol.min-1.kg-1, followed by a delayed further increase that matched Rd 11-22 min after the onset of exercise. The plasma glucagon-to-insulin molar ratio fell slightly at the onset of exercise and then increased gradually. The glucagon-to-insulin ratio was correlated with Ra over the entire exercise period (r = 0.63, P less than 0.0001), but not during the early part of exercise, when Ra increased rapidly. The catecholamine- (epinephrine plus norepinephrine) to-insulin molar ratio was correlated with Ra during the early period (r = 0.52, P less than 0.01) and over the entire period of exercise (r = 0.66, P less than 0.0001). Our results confirm previous demonstrations that the glucagon-to-insulin molar ratio is an important regulator of Ra during exercise. We hypothesize that the catecholamine-to-insulin molar ratio is important during the early period of exercise and possibly during late exercise as an additional regulatory factor to the glucagon-to-insulin molar ratio.

Animals↗
PubMed1992

Estimation of glucose production during exercise with a one-compartment variable-volume model.

A variable-volume one-compartment model of glucose kinetics and step increases in the rate of tracer infusion were examined for estimation of endogenous glucose production (Ra) during moderate exercise in dogs. A primed infusion of D-[3-3H]glucose was left constant or increased 1.5-, 2-, 3-, 4-, or 5-fold at the onset of a 60-min period of exercise. Application of a regression method, in which Ra and the effective distribution volume were estimated over time, revealed dynamic changes in Ra that were not evident during the constant tracer infusion with a fixed-volume model. Application of the fixed-volume model to studies performed with a two- or three-fold step increase in tracer resulted in the lowest sum-of-squares difference from the regression method. Our results demonstrate that application of a variable-volume model can be achieved during exercise by enrichment of the plasma specific activity through step increases in the rate of tracer infusion and application of a regression method. Alternately, estimates of Ra with a fixed-volume model can be improved by enrichment of the plasma specific activity through a single step increase in the rate of tracer infusion. Our results suggest that when endogenous Ra is changing rapidly, such as at the onset of exercise, these methods will provide a more accurate estimate of Ra than the standard fixed-volume model and constant tracer infusion.

Animals↗
PubMed1992

Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.

It has been hypothesized that insulin resistance and hyperinsulinemia contribute to the development of arterial hypertension. To further investigate this relationship, we compared arterial blood pressure in controls and women with polycystic ovary syndrome (PCO), an insulin-resistant state. Fourteen PCO women and 18 normal control women of similar age, body mass index, and race were studied. Plasma glucose and insulin levels were determined in an oral glucose tolerance test. The insulin sensitivity (SI) index was determined by the minimal model method. Systolic and diastolic blood pressure were measured by 24-h ambulatory monitoring. Left ventricular mass was assessed by echocardiography. The two groups had comparable fasting glucose levels, but the 2-h postload glucose was higher in PCO (8.0 +/- 0.5 vs. 5.6 +/- 0.3 mmol/L; P less than 0.001). Compared to controls, PCO women were significantly more insulin resistant by fasting insulin, 2-h insulin concentrations, and SI (28.3 +/- 6.7 vs. 68.3 +/- 10.0 min-1/nmol.mL; P less than 0.01). Average ambulatory systolic (121 +/- 2 vs. 118 +/- 2 mm Hg) and diastolic (76 +/- 2 vs. 73 +/- 2 mm Hg) blood pressures were similar for PCO and control women. No difference was found in left ventricular mass. Therefore, despite profound insulin resistance and hyperinsulinemia, women with PCO do not have increased arterial pressure or left ventricular mass.

Adult↗
PubMed1992

Markedly reduced beta-cell function does not result in insulin resistance in islet autografted dogs.

Autotransplantation of islets of Langerhans has resulted in long-term normoglycemia in pancreatectomized dogs. This canine model is useful in evaluating both the progress of islet transplantation and the effect of a reduced islet mass upon the determinants of glucose tolerance: i.e., insulin secretion, insulin sensitivity, and glucose effectiveness. To determine the effect of a reduced islet mass on these factors, we measured the acute insulin response to arginine (AIRa) and glucose (AIRg), the slope of glycemic potentiation of AIRa (SP), insulin sensitivity (Sl), and glucose effectiveness (SG) in control (CN), diabetic (DM), and pancreatectomized dogs rendered normoglycemic with transplanted autografts of islets of Langerhans (TX). Normal fasting plasma glucose (FPG) (TX 4.7 +/- 0.2 mM; CN 4.9 +/- 0.1 mM; P greater than 0.05) was maintained despite a markedly reduced insulin secretion in TX (AIRa 24%, AIRg 15%, and SP 11% of CN). All measures of insulin secretion were significantly correlated (SP vs. AIRg, r = 0.80, P less than 0.0001; AIRa vs. AIRg, r = 0.92, P less than 0.0001) across all animals, but none of the measures of secretion were significantly correlated with either the number of islets transplanted or time posttransplant (P greater than 0.10). Insulin sensitivity was normal in islet autografted dogs (TX: 136 +/- 12 min-1/(nmol/ml); CN: 101 +/- 11 min-1/(nmol/ml), P greater than 0.05) but SG was reduced (TX: 1.93 +/- 0.28 x 100 min-1; CN: 3.53 +/- 0.35 x 100 min-1, P less than 0.05), as determined by the minimal-model method. In diabetic animals (FPG = 16.1 +/- 1.3 mM), insulin secretion was negligible by all measures (P greater than 0.05), and was associated with insulin resistance (Sl = 28 +/- 8 min-1/(nmol/ml)) and reduced SG (1.72 +/- 0.11 x 100 min-1). These studies indicate that across a range of insulin secretion in dogs, the secretagogues arginine and glucose provide similar estimates of beta-cell function. This markedly reduced beta-cell function does not result in insulin resistance when fasting normoglycemia is maintained, but is associated with a decrease in glucose action at basal insulin.

Animals↗
PubMed1990

Glucoregulatory response to moderate exercise in long-term islet cell autografted dogs.

The glucoregulatory response to moderate treadmill exercise (approximately 60% maximum heart rate; 60 min at 100 m/min, 12% grade) was examined in six controls and six pancreatectomized dogs that had been normoglycemic and insulin independent for more than 1 year since autograft of isolated islets of Langerhans (Tx). There were no significant intergroup differences in plasma glucose levels during exercise, but return to baseline after exercise was delayed in Tx (p less than 0.05). In Tx, the initially suppressed insulin levels rose above baseline from 30 to 60 min. Within Tx, exercise-induced levels of plasma glucagon and epinephrine were more variable than control and strongly correlated (r = 0.81, p less than 0.001), perhaps indicating that the A cells within the grafted islets were regulated by circulating beta-adrenergic agonists. We conclude that the isolated islets were removed from direct central control. In Tx dogs, the variable counterregulatory responses and the diminished recovery of plasma glucose after exercise indicate reliance on alternative glucoregulatory mechanisms.

Adrenal Glands↗